Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer by Kahlert, Christoph et al.
RESEARCH ARTICLE Open Access
Low expression of aldehyde deyhdrogenase 1A1
(ALDH1A1) is a prognostic marker for poor
survival in pancreatic cancer
Christoph Kahlert
1*, Frank Bergmann
2, Janine Beck
1, Thilo Welsch
1, Carolin Mogler
2, Esther Herpel
2, Shamik Dutta
1,
Thomas Niemietz
1, Moritz Koch
1 and Jürgen Weitz
1
Abstract
Background: Aldehyde deyhdrogenase 1 (ALDH1) has been characterised as a cancer stem cell marker in different
types of tumours. Additionally, it plays a pivotal role in gene regulation and endows tumour cells with augmented
chemoresistance. Recently, ALDH1A1 has been described as a prognostic marker in a pancreatic cancer tissue
microarray. The aim of this study was to reevaluate the expression of ALDH1A1 as a prognostic marker on whole-
mount tissue sections.
Methods: Real-time-quantitative-PCR (qRT-PCR) and Western blotting were used to evaluate the expression profile
of ALDH1A1 in seven pancreatic cancer cell lines and one non-malignant pancreatic cell line. Immunostaining
against ALDH1A1 and Ki-67 was performed on paraffin-embedded samples from 97 patients with pancreatic
cancer. The immunohistochemical results were correlated to histopathological and clinical data.
Results: qRT-PCR and Western blotting revealed a different expression pattern of ALDH1A1 in different malignant
and non-malignant pancreatic cell lines. Immunohistochemical analysis demonstrated that ALDH1A1 was confined
to the cellular cytoplasm and occurred in 72 cases (74%), whereas it was negative in 25 cases (26%). High
expression of ALDH1A1 was significantly correlated to an increased proliferation rate (Spearman correlation, p =
0.01). Univariate and multivariate analyses showed that decreased expression of ALDH1A1 is an independent
adverse prognostic factor for overall survival.
Conclusions: Immunonhistochemical analysis on whole-mount tissue slides revealed that ALDH1A1 is more
abundantly expressed in pancreatic cancer than initially reported by a tissue microarray analysis. Moreover, high
expression of ALDH1A1 correlated significantly with the proliferation of tumour cells. Intriguingly, this study is the
first which identifies low expression of ALDH1A1 as an independent adverse prognostic marker for overall survival
in pancreatic cancer.
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Background
Although the incidence of pancreatic cancer amounts
only to 3% of all tumours, it is a major cause of cancer-
related death in Western countries [1]. Surgical resec-
tion remains the only potentially curative therapeutic
option. At the time of initial diagnosis, only a minority
of patients with pancreatic cancer are still in a curable
resectable stage [2]. Even if a potentially curative resec-
tion can be performed, the five-year overall survival is
low at 10-25% [2-4].
Current prognostic markers for curatively resected
pancreatic cancer include lymph node status, tumour
type and histological grade [2,4,5]. However, these prog-
nostic markers only poorly predict metastatic progression
or tumour response to medical treatment in the indivi-
dual patient. Therefore new biomarkers are required in
order to stratify patients into different risk categories,
thus allowing a more specific treatment regimen.
* Correspondence: christoph.kahlert@med.uni-heidelberg.de
1Department of General, Visceral and Transplantation Surgery, Im
Neuenheimer Feld 110, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
Kahlert et al. BMC Cancer 2011, 11:275
http://www.biomedcentral.com/1471-2407/11/275
© 2011 Kahlert et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Stem cell markers are a promising group of new bio-
markers. In pancreatic cancer, several surface markers
have been identified to provide a subpopulation of the
tumour cells with so-called stem cell characteristics.
These cancer stem cell markers include CD44 [6], CD24
[6] and CD133 [7]. Their relevance as strong prognostic
markers in pancreatic cancer has already been evaluated
[8,9].
In this study, we have focused on aldehyde dehydro-
genase 1A1 (ALDH1A1), which has been recently identi-
fied to label tumour stem cells in breast cancer [10],
colon cancer [11] lung cancer [12] and head and neck
squamous cancer [13]. ALDH1 belongs to the superfam-
ily of NAD(P)(+)-dependent enzymes which metabolise
a wide spectrum of endogenous and exogenous aliphatic
and aromatic aldehydes [14]. It is distributed ubiquiti-
tously in many human tissues where it is localised in
the cellular cytoplasm. By the formation of retinoic acid
it acts as a pivotal modulator for gene regulation and
cell differentiation [14]. Moreover, ALDH1 has a strong
activity for detoxifying aldophosphamide, hence provid-
ing overexpressing cells with chemoresistance against
cyclophosphamide [15].
Besides to gynaecological tumours and tumours of
the respiratory tract [10,12,16], increased expression of
ALDH1A1 in a pancreatic cancer tissue microarray has
been recently described to correlate with a dismal
prognosis [17]. On the contrary, increased expression
of ALDH1 in ovarian cancer correlates with more
favourable disease-free and overall survival [18]. Con-
versely, overexpression of ALDH1 in colorectal cancer
is not related to differences in survival at all [19].
However, most of these results are based on tissue
microarrays. This method is a very sophisticated tool
to screen a large number of clinical specimens, but it
might obscure essential findings by evaluating only
small punched random samples from morphologically
representative tissue areas. Hence, the aim of our
study was to reevaluate the expression pattern of
ALDH1A1 in pancreatic cancer on whole-mount tissue
slides and to correlate these results with clinical and
pathological data. Furthermore, ALDH1-positive non-
pancreatic tumour cells have been found to have a
high Ki-67 expression [12,20,21]. Therefore, we
focused on the correlation between the expression of
ALDH1A1 and the proliferation rate of tumour cells in
pancreatic cancer samples. Our study demonstrates
that high expression of ALDH1A1 is significantly cor-
related with the proliferation rate of pancreatic tumour
cells. Intriguingly, this study is the first which identifies
low expression of ALDH1A1 as an independent
adverse prognostic marker for overall survival in pan-
creatic cancer.
Methods
Patients
Paraffin-embedded samples of primary pancreatic ductal
adenocarcinoma from a consecutive series of 97
patients, who underwent tumour resection between
2002 and 2005 at the Department of General, Visceral,
and Transplantation Surgery, University of Heidelberg,
were included in this study. Previously, we had evaluated
the prognostic significance of CD166 in this patient
cohort [22]. No neoadjuvant radio- or chemotherapy
was applied prior to surgical resection in any patient.
After resection, 70 patients were subjected to adjuvant
chemotherapy. The median observation period for over-
all survival was 18.3 months. Paraffin-embedded tumour
samples were provided from the tissue bank of the
National Centre for Tumour disease (NCT) Heidelberg.
The tissue sampling and the analyses regarding potential
prognostic markers were approved by the University of
Heidelberg Ethics Committee. Table 1 displays the clini-
cal and histopathological characteristics of the patients.
Immunohistochemistry
Immunohistochemical staining for ALDH1A1 was per-
formed as previously described [22]. Briefly, 1-2 μm
sections of formalin-fixed, paraffin-embedded tumour
samples were mounted on object slides (SUPER-
FROST
® PLUS microscope slides, Menzel, Braunsch-
weig, Germany) and incubateda t3 7 ° Co v e r n i g h t .A f t e r
de-waxing in xylene and ethanol, antigen retrieval was
achieved by boiling in a microwave oven for 5 min
(pH 6.0, 0.94 ml Antigen Unmasking Solution (Vector
Laboratories, Burlingame, CA, USA)/100 ml distilled
water) three times. After immersing slides in a 3.0%
hydrogen peroxidase solution in methanol for 20 min
in order to inhibit endogenous peroxidase activity,
non-specific binding sites were blocked by pre-incuba-
tion with 10% normal goat serum (Vector Labora-
tories) in 1 mol/L PBS for 30 min at room
temperature. Primary antibodies against ALDH1A1
(mouse IgG1, clone 44, BD Transduction Labora-
tories™, Europe, dilution 1:200, rabbit IgG, clone
EP1933Y, Novus Biologicals, USA, 1:200, Rabbit poly-
clonal, Novus Biologicals, USA 1:50) and the IgG -
negative control (mouse IgG, BD Pharmingen, Europe,
1:100) were incubated at 4°C overnight. Slides were
loaded with secondary antibody coupled to peroxidase-
conjugated polymers (EnVision
®+ System, DakoCyto-
mation A/S, Denmark) for 30 minutes. Afterwards, the
immunoreaction was visualised by using AEC Substrate
Chromogen (DakoCytomation A/S) according to the
instructions of the manufacturer. Eventually, sections
were counterstained with haematoxylin, dehydrated in
graded concentrations of ethanol and mounted.
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bank of the National Centre for Tumour Disease (NCT)
Heidelberg by means of an automated immunostainer
(Dako Autostainer A/S, Denmark) according to the
manufacturer’s instructions. Briefly, paraffin was
removed with xylene and ethanol before the sections
were de-masked for 15 min (pH 6.0, 0.94 ml Antigen
Unmasking Solution, (Vector Laboratories)/100 ml dis-
tilled water). The slides were loaded with the primary
antibody (Ki-67, Dako, A/S Denmark 1:200) and with
the secondary antibody (Dako REAL Biotinylated
Secondary Antibodies A/S Denmark) for 30 minutes,
respectively. As the detection system, a streptavidin-
peroxidase complex (Dako REAL Detection System) was
used and the reactions were visualised by using Dako
REAL AEC/H2O2 Substrate Solution (CHROM). Finally,
the slides were counterstained with haematoxylin.
Evaluation of immunohistochemistry was performed
by scanning the whole section at medium (50×) and
high magnification (200×). Staining intensity and the
percentage of positive tumour cells in the whole section
were estimated by three independent researchers (CK,
JB, NM) and two pathologists (CM, FB) on a blind
basis. A multi-head microscope was used and consensus
was reached for each slide. The staining intensity was
classified as absent: 0, weak: 1, medium: 2 and strong: 3.
The percentage of positive cells was categorised as 0: (<
5%), 1 (5-25%), 2 (> 25%-50%), 3 (> 50%-75%), and 4 (>
75%). By multiplying the value of the staining intensity
with the categorised value of positive cells, a final
immunohistochemical score was obtained. This scoring
system has been suggested as a tool to evaluate prognos-
tic biomarkers with broadly different levels of expression
and intensity [23]. The proliferation rate of each tumour
specimen was determined on a blind basis by categoris-
ing the estimated number of tumour cells stained posi-
tive against Ki-67 as 0: (< 5%), 1 (5-15%), 2 (> 15%-
25%), 3 (> 25%).
Cell lines
The following cell lines were used: SU8686, BxPC3,
PANC-1, AsPC-1, MiaPaCa-2, ACBRI (all purchased
from the American Type Culture Collection (ATCC),
Manassas, VA 20108, USA), Colo357 (provided by T.
Welsch) as well as T3M-4 (Cell Bank, RIKEN BioRe-
source Centre, Japan). In June 2010, the cell lines were
re-tested and re-authenticated by analysing cell samples
for eight polymorphic short random repeat (STR) loci
(Deutsche Sammlung von Mikroorganismen und Zellk-
ulturen GmbH (DSMZ), Braunschweig, Germany).
Tumour cell lines were maintained in RPMI-1640
(Sigma, St. Louis, MO), supplemented with 10% (v/v)
foetal calve serum (FCS), 100 U/ml penicillin and 100
μg/ml streptomycin. ACBRI cells were maintained in
CSC Certified Complete Medium (CellSystems). All cells
were cultured in a humidified atmosphere of 5% CO2 at
37°C.
Total RNA isolation and real-time qPCR
Total RNA from the cell lines was extracted employing
the RNeasy Mini Kit (Qiagen, Hilden, Germany) follow-
ing the instruction manual. One microgram of total
RNA was reverse transcribed using the miScript Reverse
Transcription Kit (Qiagen). Ten nanograms of the
resulting cDNA were used for quantification by qPCR
(SYBR Green PCR Kit, Qiagen) in a Roche Light
Cycler™ (Roche Diagnostics GmbH, Mannheim,
Table 1 Correlation between expression of ALDH1A1 in
pancreatic cancer and clinical and pathological
parameters
Characteristics Number of
cases
ALDH1A1
Low
ALDH1A1
High
P-Value
Total 97 59 38
Age
< mean 65
years
46 25 21 0.215
≥ mean 65
years
51 34 17
Gender
Female 44 30 14 0.18
Male 53 29 24
Lymph node
status
N0 18 11 7 0.98
N1 79 48 31
Grading
1 4 2 2 0.83
25 7 3 4 2 3
33 6 2 3 1 3
AJCC tumour
stage
2 18 11 7 0.18
37 4 4 3 3 1
45 5 0
R-Status
88 53 35 0.70
96 3
ALDH1A1
Low: percentage of positive cells ≤ median percentage of positive
cells; ALDH1A1
High: percentage of positive cells > median percentage of
positive cells. P-Value evaluated by the Chi-square (c
2) test.
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and 18S were purchased from Qiagen (Hs_ALD-
H1A1_1_SG QuantiTect Primer Assay, Cat. No.
QT00013286 and Hs_RRN18S_1_SG QuantiTect Primer
Assay, Cat. No. QT00199367). After an initial incubation
at 95°C for 10 minutes, 40 cycles were carried out (15
sec at 95°C, 15 sec at 60°C, 30 sec at 72°C). All experi-
ments were performed as triplicates. ALDH1A1 expres-
sion was normalised to 18 s and quantified as previously
described [24].
Western blotting
Cells were separated with 2 ml Accutase (PAA Cell
Culture Company), washed with PBS and lysed in a
cell lysis buffer (RIPA) with a protease inhibitor (Com-
plete Mini, Roche Applied Science, Mannheim, Ger-
many). Subsequently, they were disrupted by
sonication and the protein concentration of the super-
natant (centrifugation: 10 min, 11000 rpm, 4°C) was
determined by a BCA kit (Thermo Scientific, Schwerte,
Germany). Thirty micrograms of protein were sepa-
rated on a 10% SDS-PAGE gel, transferred to a nitro-
cellulose membrane (BioRad, Munich, Germany) and
incubated with antibodies against ALDH1A1 (Mouse
I g G 1 ,c l o n e4 4 ,B DT r a n s d u c t i o nL a b o r a t o r i e s ™)a n d
a/ß-Tubulin (Cell Signaling Technology, Danvers, MA
01923, USA) with a dilution of 1:500. The horseradish
peroxidase-conjugated secondary antibody anti-rabbit
or anti-mouse (Sigma-Aldrich, Munich, Germany) was
added at a dilution of 1:1000 after repeated washing
with a wash/blocking buffer (PBS, Tween20 0.1% (v/v),
skim milk powder 7,5% (w/v)). The antigen-antibody
complexes were detected by using an ECL kit (Thermo
scientific, Schwerte, Germany) according to the manu-
facturer’s recommendations. All experiments were per-
formed as triplicates.
Statistical analysis
The software package SPSS, version 11.0 (SPSS, Chi-
cago, IL, USA) was used for all calculations. The Chi-
square (c
2) test was applied to examine the correlation
between ALDH1A1 expression and clinical and patholo-
gical parameters. The Spearman correlation was
employed for determining a correlation between the
expression of ALDH1A1 and Ki-67. The Kaplan-Meier
method was used to visualise overall and recurrence free
survival curves, and differences between survival curves
were assessed with the log-rank test for univariate
analysis.
The Cox proportional hazards regression model was
conducted on all covariates that showed a significant
association with overall survival in the univariate analy-
sis. The P-values of all statistical tests were two-sided
and P < 0.05 was considered significant.
Results
Evaluation of specificity of ALDH1A1
immunohistochemistry
To validate the specificity of immunohistochemical stain-
ing against ALDH1A1, we repeated immunohistochemis-
try in 10 representative specimens with three different
antibodies against ALDH1A1 and one IgG negative con-
trol. When comparing the immunohistochemical results
of the three antibodies in sequential sections, they dis-
played similar cytoplasmic expression patterns in pan-
creatic cancer and in non-malignant cells, though the
staining intensity of the polyclonal antibody was weaker
than the staining intensity of the monoclonal antibodies
(data not shown). These results, in addition to the Wes-
tern blot analysis, confirmed the specificity of the anti-
ALDH1A1 staining. For immunohistochemical evalua-
tion of all clinical specimens, we used only the mouse
monoclonal antibody (mouse IgG1, clone 44, BD Trans-
duction Laboratories™, Europe), which had been pre-
viously used successfully [10,12,18,20].
Expression of ALDH1A1 in pancreatic cell lines
In seven pancreatic cancer cell lines and one primary
pancreatic epithelial cell line, we assessed the expres-
sion of ALDH1A1 by real-time qPCR and Western
blotting (Figure 1A and 1B). This analysis showed a
Figure 1 (A) Gene expression analysis of ALDH1 by qPCR in
seven pancreatic cancer cell lines and one non-malignant
pancreatic cell line. Fold-change (y-axis) of ALDH1 expression in
pancreatic cancer cell lines compared to the non-malignant
pancreatic epithelial cell ACBRI, respectively. (B) Western blotting
analysis of ALDH1A1 in seven pancreatic cancer cell lines and one
non-malignant pancreatic cell line (8). MW a/b-tubulin as loading
control. 1: BxPC3, 2: T3M4, 3: MiaPaCa-2, 4: AsPC-1, 5: Colo357, 6:
Panc1, 7: SU8686:, 8: ACBRI.
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cell lines. By qPCR, ALDH1A1 was below the detec-
tion threshold in BxPC3, T3M4 and PANC1. In
SU8686 and Colo-357, gene transcripts of ALDH1A1
were down-regulated by a 0.07- and 0.5-fold change
respectively, compared to the non-malignant epithelial
pancreatic cell line. In AsPC-1, ALDH1A1 was
increased by 9-fold and in MiaPaCa-2 by 3-fold com-
pared to ACBRI cells. These results were in good line
with the Western blot analysis (Figure 1B). In sum-
mary, these data may be helpful for further in vitro
studies when assessing the relevance of ALDH1A1 in
pancreatic cancer.
Expression of ALDH1A1 and Ki-67 in normal pancreatic
tissue and pancreatic cancer cells
In non-malignant pancreatic tissue, adjacent to pancrea-
tic cancer in 60 cases, we observed strong cytoplasmic
expression of ALDH1A1 in the pancreatic islet cells, in
the acinar epithelium and in the ductal epithelial cells.
The staining intensity displayed a homogenous pattern:
islet cells usually revealed a strong staining intensity,
while acinar and ductal epithelial cells revealed a moder-
ate staining intensity.
In pancreatic cancer, the expression of ALDH1A1 was
confined to the cellular cytoplasm and occurred in 72
cases (74%), whereas it was negative in 25 cases (26%)
(Figure 2A-D). There was no distinct difference in
expression between the tumour center and the tumour
invasion front. The distribution of staining intensity was
as follows: intensity 0 in 25 samples (26%), intensity 1 in
13 samples (13%), intensity 2 in 29 samples (30%), and
intensity 3 in 30 (30%) samples.
The percentage of positive cells was categorised as
follows: 0 (< 5%): 25 samples (26%), 1 (5-25%): 18
samples (18%), 2 (26-50%): 16 samples (17%), 3
(51-75%): 18 samples (18%), 4 (> 75%): 20 samples
(21%). As already previously reported in a small
cohort of patient samples [25], high expression of
ALDH1A1 was more often observed in well-differen-
tiated tumours, though the correlation between
expression and tumour grades did not reach statistical
significance (Table 1).
The distribution of ALDH1A1 expression according to
the immunohistochemical score was: 0: 25 samples, 1: 8
s a m p l e s ,2 :1 0s a m p l e s ,3 :5s a m p l e s ,4 :1 1s a m p l e s ,6 :
11 samples, 8: 3 samples, 9: 8 samples and 12: 17
samples.
The percentage of Ki-67 positive cells was categorised
as follows 0 (< 5%): 27 samples (28%), 1 (5-15%): 27
samples (28%), 2 (> 15%-25%): 23 samples (23%), 3 (>
25%): 20 samples (21%). There was no difference in
staining intensity among all samples.
Relationship between the expression of ALDH1A1 and
Ki-67
Recently, ALDH1 positive tumours have been found to
have a high Ki-67 expression and to correlate positively
with an increased proliferative capacity in vitro
[12,20,21]. Therefore, we performed immunostaining
against Ki-67 in consecutive sections and compared the
percentage of Ki-67 positive cells with the immunohisto-
chemical score of ALDH1A1 in pancreatic cancer
(Figures 2E-H). The correlation between the proliferation
rate and the immunohistochemical score of ALDH1A1
expression was shown to be significant (p = 0.01).
Low expression of ALDH1A1 is an independent
prognostic marker in pancreatic cancer
To compare the expression of ALDH1A1 with clinical and
pathological parameters, samples were grouped as ALD-
H1A1
Low (immunohistochemical score ≤ median immuno-
histochemical score = 4) and as ALDH1A1
High
(immunohistochemical score > median immunohistochem-
ical score = 4). The Chi-square test revealed no significant
correlation between ALDH1A1 expression to age, gender,
lymph node status, grading, American Joint Cancer Com-
mittee (AJCC) tumour stage, or resection status (Table 1).
By univariate analysis using the log-rank test, patients
with ALDH1A1
Low tumours displayed significantly
reduced median overall survival and recurrence-free sur-
vival compared to patients with ALDH1A1
High tumours
(ALDH1A1
Low: median overall survival 16.3 months,
ALDH1A1
High: median overall survival 32.2 months, p =
0.012, ALDH1A1
Low: recurrence-free survival 11
months, ALDH1A1
High: recurrence-free survival 17
months, p = 0.029) (Figure 3A and 3B). Furthermore,
univariate analysis by the log-rank test demonstrated
lymph node status, AJCC tumour stage and treatment
with adjuvant chemotherapy to be significant prognostic
parameters as described recently [22] (Table 2). Univari-
a t ea n a l y s i sf o rt h ee x p r e s s ion of Ki-67, performed by
categorising the tumour samples into Ki-67
Low (prolif-
eration rate ≤ median proliferation rate = 15%) and Ki-
67
High (proliferation rate > median proliferation rate =
15%) showed no significant difference for overall survi-
val and recurrence-free survival (Ki-67
Low: median over-
all survival 21.8 months, Ki-67
High:m e d i a no v e r a l l
survival 17.7 months, p = 0.27, Ki-67
Low: recurrence-free
survival 14 months, Ki-67
High: recurrence-free survival
15 months, p = 0.78). These results are in accordance
with previous observations [26,27].
Multivariate analysis with the Cox proportional
hazards regression model was performed to identify
independent prognostic markers for overall survival.
Low expression of ALDH1A1 was found to be an inde-
pendent prognostic marker for overall survival (p =
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and treatment with adjuvant chemotherapy (p = 0.0001)
(Table 3). Lymph node status was not included into the
multivariate analysis due to its linear depending covar-
iance with AJCC stage. Similar to the univariate analysis,
ALDH1A1 was the only significant prognostic variable
for recurrence-free survival in the multivariate analysis
(p = 0.017). AJCC tumour stage and treatment with
adjuvant chemotherapy had no significant impact as
prognostic markers on recurrence-free survival by uni-
variate analysis or by multivariate analysis.
Subgroup analysis of ALDH1A1 expression in patients
with adjuvant chemotherapy and no adjuvant treatment
Adjuvant chemotherapy has improved survival in
patients with pancreatic cancer significantly [28]. The
Figure 2 Immunohistochemical analyses of ALDH1 in pancreatic cancer revealed a cytoplasmic expression varying from 0 - 3.
Comparing expression of ALDH1 and Ki-67 in corresponding sequential slides resulted in a positive correlation between strong expression of
ALDH1 and a high proliferation rate. (A - D): pancreatic tumour samples displaying cytoplasmic expression of 0 (A), 1 (B), 2 (C) and 3 (D). (E - H):
corresponding sequential slides with immunohistochemical staining against Ki-67. Original magnification 200×.
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to stratify patients into different risk groups and to
refine the selection of therapeutic agents being used in
the postoperative setting. In this context, ALDH1 has
been described as predictive marker in different types of
tumour. In leukaemia and breast cancer, ALDH1 pro-
vides tumour cells with increased resistance against che-
motherapeutical agents such as cyclophosphamide
[15,29]. However, data also exist showing that increased
expression of ALDH1 is associated with an improved
response to chemotherapy in ovarian cancer [18]. For
that reason, we performed a univariate analysis for the
subgroup of patients having received adjuvant che-
motherapy (n = 69) and for the subgroup of patients
having not received adjuvant treatment (n = 19) to eval-
uate the role of ALDH1A1 as predictive marker for
adjuvant chemotherapy. Nine patients with unknown
adjuvant treatment were excluded. In this analysis, we
identified strong expression of ALDH1A1 as a signifi-
cant prognostic marker for more favourable overall sur-
vival in the subgroup of patients having been treated
with adjuvant chemotherapy. Likewise, augmented
expression of ALDH1A1 showed a trend for more
favourable recurrence-free survival, though the level of
significance failed (ALDH1A1
Low: median overall survi-
val 19.8 months, ALDH1A1
High: median overall survival
33.0 months, p = 0.03, ALDH1A1
Low: recurrence-free
survival 11,9 months, ALDH1A1
High: recurrence-free
survival 17 months, p = 0.07) (Figure 4A and 4B).
A multivariate analysis including AJCC stage confirmed
ALDH1A1
High in the subgroup of patients having received
adjuvant chemotherapy as a significant prognostic marker
Figure 3 Kaplan-Meier curves displaying (A) median overall
survival and (B) median recurrence-free survival in 97 patients
with pancreatic cancer and ALDH1
negative/low or ALDH1
high
expression.
Table 2 Univariate analysis for prognostic parameters in
pancreatic cancer for median overall survival (OAS) and
median recurrence-free (RFS).
Characteristics RFS* OAS
No.
of
Cases
Time
(months)
P-
Value
No.
Of
cases
Time
(months)
P-
Value
Adjuvant
Chemotherapy†
Not received 14 7 0.6 18 4.5 0.0001
Received 65 15 69 22.8
Lymph node
status
N0 16 24 0.34 18 32.2 0.04
N1 64 12 78 17.7
AJCC tumour
stage
2 16 24 0.28 18 32.2 0.001
3 59 12 73 18.7
4 5 6 5 10.9
ALDH1A1
Low 47 11 0.029 58 16.3 0.012
High 33 17 38 32.3
Total number of cases only 79, in 12 cases the exact time of tumour
recurrence could not be specified.
† Type of adjuvant treatment in 9 cases is unknown.
Multivariate analysis (Cox regression model) of prognostic parameters for
overall survival in pancreatic cancer
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variate analysis with adjuvant chemotherapy was excluded
for its linear depending covariance (Table 4).
In the smaller subgroup of patients having not
received chemotherapy postoperatively with adjuvant
intentions (n = 19), different expression of ALDH1A1
had no significant impact as a prognostic marker on
overall survival (p = 0.74) by univariate analysis nor on
recurrence-free survival (p = 0.35) by univariate analysis.
Discussion
In our study, we have demonstrated that low expression
of ALDH1A1 is an independent prognostic marker for
shortened disease-free and overall survival in ductal ade-
nocarcinoma of the pancreas. These results are very
conflicting to a recent published study by Rasheed et al.,
who have described increased expression of ALDH1A1
in pancreatic cancer to correlate with a dismal prognosis
[17]. Since Rasheed et al. have evaluated the expression
of ALDH1A1 by tissue microarrays, whereas we per-
formed our immunohistochemical analysis on whole-
mount tissue slides, methodological differences may
explain these opposing results. However, by evaluating
whole-mount tissue slides, we found ALDH1A1 to be
expressed very heterogeneously within the tumour bulk.
In fact, while Rasheed et al. claimed only 34% of the
immunostained tumour samples as positive, we observed
a much higher fraction of 74% of tumour specimen to
b ep o s i t i v e .H e n c e ,u s i n go n l y0 . 6m mr a n d o mt i s s u e
samples from morphologically representative tissue
areas might obscure essential findings and result in an
increased rate of false-negative results.
However, akin to the observations by Morimoto et al.
in breast cancer [20] and by Jiang et al. in lung cancer
cell lines [12], we have found a positive correlation
between an increased expression of ALDH1A1 and a
higher proliferation rate. Furthermore, we observed
strong expression of ALDH1A1 more frequently in well-
differentiated tumour samples. With these findings, it is
tempting to hypothesise, as to why overexpression of
ALDH1A1 correlates with a more favorable clinical out-
come: assuming that conventional cytotoxic therapy
aims mainly at the proliferating, differentiated cellular
fraction, it can be conjectured that overexpression of
ALDH1A1 is associated with a biological type of tumour
which is more prone to chemotherapy. This hypothesis
is supported by our findings, that increased expression
of ALDH1A1 has been identified as a strong prognostic
marker for improved clinical outcome in our subgroup
analysis for patients having received adjuvant che-
motherapy but not in the subgroup of patients having
not received adjuvant treatment. Due to the low patient
number in this subgroup of patients, however, this
Table 3 Multivariate analysis (Cox regression model) of prognostic parameters for overall survival in pancreatic cancer
Characteristics Beta Standard Error Wald Df Relative Risk 95% CI of Relative Risk P- Value
ALDH1A1
Expression negative/low vs. High -0.923 0.293 9.964 1 0.397 0.224-0.705 0.002
AJCC stage 0.891 0.288 9.592 1 2.438 1.387-4.286 0.002
Adjuvant chemotherapy vs. no adjuvant chemotherapy -1.813 0.311 33.916 1 0.163 0.089-0.300 0.0001
Figure 4 Kaplan-Meier curves displaying (A) median overall
survival and (B) median recurrence-free survival in a subgroup
analysis of patients having received adjuvant chemotherapy.
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Page 8 of 10needs to be confirmed in further studies. In addition,
our assumptions are in line with the clinical results of
Chang et al., who reported a significant correlation
between high expression of ALDH1 in ovarian cancer
and response to chemotherapy [18]. Bearing in mind
that ALDH1 increases chemoresistance against cyclo-
phosphamide, one can argue that this chemotherapeutic
agent is not part of the standard chemotherapy regimen
against pancreatic cancer. Moreover, increased chemore-
sistance against cyclophosphamide by ALDH1 does not
exclude increased chemosensitivity to other chemothera-
peutic agents. Regarding our in vitro data, we have
shown that MiaPaca2 cells have a strong expression of
ALDH1A1. Intriguingly, Monti et al. have demonstrated
that MiaPaca2 cells exhibit the strongest response to
chemotherapy when exposed to combined treatment
with gemcitabine and 5-FU [30]. These data would
favour the hypothesis that increased expression of
ALDH1A1 is not necessarily related to increased general
chemoresistance but depends on the chemotherapeutical
agent.
Conclusion
In summary, our study describes low expression of
ALDH1A1 as an independent prognostic marker for a
poor clinical outcome in pancreatic cancer on whole-
mount tissue slides. These data are conflicting with a
previous report, which has claimed increased expression
of ALDH1A1 to be an adverse prognostic marker in a
retrospective study. Therefore, to evaluate the role of
ALDH1A1 as a prognostic and predictive marker for
tumour progression and response to chemotherapy in
pancreatic cancer, standarised prospective studies with a
larger number of patients are required.
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